Remove 2018 Remove Nuclear Medicine Remove Radiopharmaceuticals
article thumbnail

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Imaging Technology

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B.,

article thumbnail

NorthStar Medical Technologies, LLC Appoints Frank Scholz, Ph.D., as President and Chief Executive Officer

Imaging Technology

milla1cf Mon, 06/19/2023 - 19:27 June 19, 2023 — NorthStar Medical Technologies, LLC , a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced the appointment of Frank Scholz, Ph.D., NorthStar’s commercialized, U.S.-based

Medical 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Meet the Minnies 2024 finalists

AuntMinnie

In 2018 he received an endowed professorship from the university. Louis, MO A first-time Minnies finalist, Dmitry Beyder exemplifies how the role of the nuclear medicine technologist can evolve. Dmitry Beyder.

article thumbnail

Blue Earth Therapeutics Announces Results of Early Clinical and Preclinical Studies of Investigational 177Lu-rhPSMA-10.1 in Treatment of Prostate Cancer

Imaging Technology

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 98
article thumbnail

NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones

Imaging Technology

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical 98
article thumbnail

Generative AI, radiologist shortages feature in 2024 Minnies

AuntMinnie

In 2018, Fishman received an endowed professorship from Johns Hopkins. Beyder played a key role in launching the radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, BJH, and Siteman Cancer Center last year. from Ukraine.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.